In prostate cancer therapy, long-term androgen deprivation leads to increased FLNA expression; however, once FLNA is localized to the nucleus, it can enhance the responsiveness of castration-resistant prostate cancer cells to androgen deprivation therapy by inducing apoptosis [59,60]. The gene discussed is FLNA; the disease is prostate carcinoma.